1. Monitoring
- Author
-
Teresa, Morán, Eudald, Felip, Joaquim, Bosch-Barrera, Itziar, de Aguirre, Jose Luis, Ramirez, Carles, Mesia, Enric, Carcereny, Diana, Roa, Elia, Sais, Yolanda, García, Remei, Blanco, Silvia, Sanchez, Claudia Rosa, Villacorta, Cristina, Queralt, Jose María, Velarde, and Rafael, Rosell
- Subjects
Correction - Abstract
Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (Serum/plasma fromThirteen patients were included. Median time on osimertinib treatment was 10.6 months with a median progression-free survival of 13.6 months. Best response to osimertinib was partial response (PR), stable disease (SD) or progression (PD) in 46.1%, 30.8% and 23.1% of patients, respectively.Most of the patients were paucisymptomatic at baseline. Symptom improvement was reported in 66.6% of responder patients; while symptoms remained stable in 75% of patients with SD, and 66% of patients with PD had clinical deterioration.Three patterns of T790M changes during osimertinib treatment were identified. T790 remained detectable with PD or a short-lasting SD in 15.4% of the patients. T790M disappeared in 69.2% of patients with PR or SD. T790M disappeared, despite clinical and/or radiographic progression in 15.4% of the patients.Changes of T790M in serum/plasma in
- Published
- 2018